In this paper, we present the recent studies that describe how gene expression profiling is being used to classify specimens of breast carcinomas based on properties of the tumor, such as expression of ER and ERBB2, as well as p53 mutation status, to identify gene expression patterns related to clinical outcome and to predict therapeutic groups responsive to hormonal and chemotherapeutic agents. This evidence concerns the gene TP53 and neoplasm.